Keywords: Ratiopharm, Pfizer, Teva, Actavis, M&A
Sale of Germany’s Ratiopharm now in final stages, with Pfizer tipped as biggest bidder
Article | 03 March 2010
With several bidders having dropped by the wayside (including French major Sanofi-Aventis) since Germany’s privately-owned generic drugmaker Ratiopharm came ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
